Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s10620-013-2698-6 | DOI Listing |
Dig Dis Sci
November 2013
Department of Pathology, Hospital Universitario 12 de Octubre, Avenida de Córdoba s/n, 28041, Madrid, Spain,
Nihon Shokakibyo Gakkai Zasshi
January 2013
Department of Gastroenterology, Hepatology and Nutrition, Kurashiki Medical Center.
A 50-year-old woman was admitted to our hospital with complaints of loss of vision, diarrhea and arthralgia. She was given a diagnosis of Behçet disease and given infliximab (IFX) to halt the progression of acute vision loss. Liver damage was detected after the fourth IFX dose.
View Article and Find Full Text PDFIntern Emerg Med
June 2010
Department of Internal Medicine, University of Modena and Reggio Emilia, Policlinico di Modena-Medicina I, via Del Pozzo 71, Modena, Italy.
Despite its rarity, infliximab-related hepatitis constitutes a cutting edge and challenging problem. In December 2004, a drug warning was issued by the Food and Drug Administration to alert healthcare professionals to the risk of hepatotoxicity in course of infliximab therapy. Subsequently, several reports of probable infliximab hepatitis have been published and interest is growing in trying to elucidate the impact of these events on clinical practice.
View Article and Find Full Text PDFJoint Bone Spine
December 2008
Hepatogastroenterology Unit, Reims University Hospital, Reims, France.
We describe a patient presenting with acute hepatitis while receiving infliximab for ankylosing spondylitis. A slight increase in serum aminotransferases was first observed in this patient after 4 infusions of infliximab. The treatment was stopped after the 6th infusion when laboratory work-up revealed a 10-fold increase in serum levels of aminotransferases.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!